In a report released today, Robert Wasserman from Benchmark Co. maintained a Buy rating on Halozyme (HALO – Research Report), with a price target of $75.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Robert Wasserman has given his Buy rating due to a combination of factors including Halozyme’s impressive financial performance and strategic developments. The company reported a significant increase in revenues and earnings for the first quarter of 2025, surpassing expectations with a 35% rise in revenue and a notable increase in non-GAAP earnings per share. This strong performance was driven by the growing sales of partnered products and higher bulk sales of its proprietary enzyme.
Moreover, Halozyme has made substantial progress in its development pipeline, receiving approvals for new indications and delivery mechanisms for several products. The company also announced a new development agreement for its high-volume autoinjector product and made advancements in pre-commercial R&D programs. Additionally, Halozyme’s robust operating cash flow and increased cash reserves, alongside a new share repurchase program, further support the positive outlook. These factors, combined with an optimistic revenue and earnings forecast for 2025, underpin Wasserman’s Buy rating and the $75 price target.
In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $73.00 price target.